Myelodysplastic Syndromes
May 2020 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Authors:Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM
Institution:Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5.

2:Evolving therapies for lower-risk myelodysplastic syndromes.
Authors:Bewersdorf JP, Zeidan AM
Institution:Department of Medicine, Section of Hematology, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA.
Journal:Ann Hematol. 2020 Apr;99(4):677-692. doi: 10.1007/s00277-020-03963-1. Epub 2020 Feb 20.

3:Myelodysplastic syndrome: validation of flow cytometry multilineage score system.
Authors:Araújo HV, Correia RP, Bento LC, Vaz ADC, Sousa FA, Alexandre AM, Schimidell D, Pedro EC, Ioshida MR, Barroso RS, Bacal NS
Institution:Centro de Hematologia de Sao Paulo, Sao Paulo, SP, Brazil.
Journal:Einstein (Sao Paulo). 2020 Jan 27;18:eAO4966. doi: 10.31744/einstein_journal/2020AO4966. eCollection 2020.

4:Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
Authors:Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR, Al-Kali A
Institution:Division of Medical Oncology, University of South Alabama Mitchell Cancer Institute, Mobile, AL, USA. Division of Hematology, Department of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.
Journal:Ann Hematol. 2020 Mar;99(3):513-518. doi: 10.1007/s00277-020-03917-7. Epub 2020 Jan 23.

5:Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Authors:Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF
Institution:From Service d'Hematologie Seniors, Hopital Saint-Louis, Assistance Publique-Hopitaux de Paris and Universite Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hopital Huriez, Centre Hospitali
Journal:N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

6:Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Authors:Latagliata R, Niscola P, Fianchi L, Aloe Spiriti MA, Maurillo L, Carmosino I, Cesini L, Sarlo C, Piccioni A, Campagna A, De Luca ML, De Benedittis D, Mancini M, Breccia M, Criscuolo M, Buccisano F, Voso MT, Avvisati G, Tafuri A, De Fabritiis P, Foà R, Girmenia C
Institution:Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Journal:Hematol Oncol. 2020 Apr;38(2):189-196. doi: 10.1002/hon.2710. Epub 2020 Jan 23.

7:Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.
Authors:Roupie AL, de Boysson H, Thietart S, Carrat F, Seguier J, Terriou L, Versini M, Queyrel V, Groh M, Benhamou Y, Maurier F, Decaux O, d'Aveni M, Rossignol J, Galland J, Solary E, Willems L, Schleinitz N, Ades L, Dellal A, Samson M, Aouba A, Fenaux P, Fain O, Mekinian A
Institution:Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique-Hopitaux de Paris, Hopital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012 Pa
Journal:Autoimmun Rev. 2020 Feb;19(2):102446. doi: 10.1016/j.autrev.2019.102446. Epub 2019 Dec 13.

8:Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Authors:Jafari PA, Sadeghian MH, Miri HH, Sadeghi R, Bagheri R, Lavasani S, Souri S
Institution:Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: Department of Pharmacodynamics and Toxicology, School of Pharmacy Mashhad University of Medical Sciences, Mashhad, Iran.
Journal:Crit Rev Oncol Hematol. 2020 Jan;145:102832. doi: 10.1016/j.critrevonc.2019.102832. Epub 2019 Nov 15.

9:Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
Authors:Gondek LP, DeZern AE
Institution:Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Journal:Lancet Haematol. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3.

10:Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Authors:Jiang L, Luo Y, Zhu S, Wang L, Ma L, Zhang H, Shen C, Yang W, Ren Y, Zhou X, Mei C, Ye L, Xu W, Yang H, Lu C, Jin J, Tong H
Institution:Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Journal:Cancer Sci. 2020 Feb;111(2):580-591. doi: 10.1111/cas.14270. Epub 2019 Dec 24.

11:Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Authors:Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, Malcovati L, Cazzola M, Ogawa S, Haferlach T, Yang H, Koeffler HP
Institution:Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Journal:Am J Hematol. 2020 Feb;95(2):133-143. doi: 10.1002/ajh.25673. Epub 2019 Nov 18.

12:The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
Authors:Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U
Institution:CHU Grenoble, Universite Grenoble Alpes, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR 5309, CS 10217, 38043, Grenoble, France. Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany.
Journal:Ann Hematol. 2020 Jan;99(1):7-19. doi: 10.1007/s00277-019-03799-4. Epub 2019 Oct 25.

13:Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Authors:Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, Patriarca F, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M
Institution:Department of Bone Marrow Transplantation, West German Cancer Centre, University of Duisburg-Essen, Essen, Germany. Electronic address: Department of Haematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland; Faculty of Medicine, University of Rzeszow, Rzeszow, Poland.
Journal:Lancet Haematol. 2020 Jan;7(1):e28-e39. doi: 10.1016/S2352-3026(19)30157-7. Epub 2019 Oct 9.

14:Iron Support in Erythropoietin Treatment in Myelodysplastic Syndrome Patients Affected by Low-Risk Refractory Anaemia: Real-Life Evidence from an Italian Setting.
Authors:Giordano G, Cutuli MA, Lucchesi A, Magnifico I, Venditti N, Vergalito F, Gasperi M, Di Marco R
Institution:Division of Internal Medicine, Hematology Service, Regional Hospital 'A. Cardarelli,', Campobasso, Italy, Department of Medicine and Health Sciences 'V. Tiberio,' University of Molise, Campobasso, Italy.
Journal:Acta Haematol. 2020;143(2):155-162. doi: 10.1159/000501329. Epub 2019 Sep 18.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount

Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 7, 2020
179 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: October 20, 2020

What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
Saint Ismier, France

"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
Rockville, Maryland

"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
Los Angeles, California

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.